These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25865683)

  • 21. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
    Jin J; Teng C; Li T
    Drug Des Devel Ther; 2018; 12():475-480. PubMed ID: 29563772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.
    Kabir ER; Azam F; Khan TTS; Yasmin H; Chowdhury NM; Ahmed SM; Sagar BH; Tahrim NA
    Cancer Med; 2024 Oct; 13(19):e70289. PubMed ID: 39387320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.
    Zhang YD; Yang Q; Jiang ZM; Ma W; Zhou SW; Xie DR
    JOP; 2011 Mar; 12(2):131-7. PubMed ID: 21386638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
    Liu L; Chen F; Zhao J; Yu H
    Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
    Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
    Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
    Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
    Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Xiao BY; Wang BC; Lin GH; Li PC
    Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy in Pancreatic Cancer: A Systematic Review.
    Hajatdoost L; Sedaghat K; Walker EJ; Thomas J; Kosari S
    Medicina (Kaunas); 2018 Jul; 54(3):. PubMed ID: 30344279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
    Petrelli F; Inno A; Ghidini A; Rimassa L; Tomasello G; Labianca R; Barni S;
    Eur J Cancer; 2017 Aug; 81():174-182. PubMed ID: 28633088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.